Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Foresee Pharmaceuticals Co's PB Ratio or its related term are showing as below:
ROCO:6576'
s PB Ratio Range Over the Past 10 Years
Min: 4.35 Med: 9.39 Max: 19.17
Current: 9.93
During the past 12 years, Foresee Pharmaceuticals Co's highest PB Ratio was 19.17. The lowest was 4.35. And the median was 9.39.
ROCO:6576's PB Ratio is ranked worse than 91.28% of 917
companies
in the Drug Manufacturers industry
Industry Median: 1.96
vs ROCO:6576: 9.93
During the past 12 months, Foresee Pharmaceuticals Co's average Book Value Per Share Growth Rate was 28.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -12.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.80% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Foresee Pharmaceuticals Co was 128.70% per year. The lowest was -16.00% per year. And the median was 3.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Foresee Pharmaceuticals Co PB Ratio Related Terms
Foresee Pharmaceuticals Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foresee Pharmaceuticals Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Foresee Pharmaceuticals Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Foresee Pharmaceuticals Co (ROCO:6576) has a PB Ratio of 9.93 as of Aug. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Foresee Pharmaceuticals Co and its competitors. This is near median its historical median of 9.39. Over the past decade, Foresee Pharmaceuticals Co's PB Ratio has ranged from 4.35 to 19.17. According to the industry distribution chart, Foresee Pharmaceuticals Co ranks #837 out of 917 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is Foresee Pharmaceuticals Co's PB Ratio too high?
Foresee Pharmaceuticals Co's current PB Ratio of 9.93 is near median its 10-year median of 9.39. Over the past 10 years, this metric has ranged from a low of 4.35 to a high of 19.17. The Drug Manufacturers industry median PB Ratio is 1.96. Foresee Pharmaceuticals Co's value of 9.93 is 406.6% above this industry median. Based on the distribution chart, Foresee Pharmaceuticals Co ranks #837 out of 917 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Foresee Pharmaceuticals Co ranks #837 out of 917 companies for PB Ratio. This places Foresee Pharmaceuticals Co in the lower half of its industry. The industry median PB Ratio is 1.96. Foresee Pharmaceuticals Co's value of 9.93 is 406.6% above this benchmark. Historically, Foresee Pharmaceuticals Co's own PB Ratio has ranged from 4.35 to 19.17 over the past decade. While the company's 10-year median is 9.39 vs. the industry median of 1.96, Foresee Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foresee Pharmaceuticals Co's current PB Ratio of 9.93 is 406.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Foresee Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foresee Pharmaceuticals Co's current PB Ratio is 9.93, which is near median its own 10-year median of 9.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$92.14, compared to a current price of NT$80.20 — trading 13% below its estimated fair value. The current PB Ratio is 9.93, which is near median its 10-year median of 9.39 and 406.6% above the Drug Manufacturers industry median of 1.96. Foresee Pharmaceuticals Co's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current PB Ratio is 9.93 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$80.20 is trading 13% below its estimated GF Value™ of NT$92.14.
GuruFocus considers Foresee Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for ROCO:6576:
PB Ratio: 9.93 (near median its 10-year median of 9.39)
GF Value™: NT$92.14 vs. price of NT$80.20 (13% below fair value)
Industry Position: 406.6% above the Drug Manufacturers median (#837 of 917)
No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
67GF Score
Get the complete analysis for ROCO:6576
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6576 has been successfully added to your 
